Thrombocytopenia Complicating Transcatheter Aortic Valve Implantation: Differences Between Two New-Generation Devices

J Cardiovasc Transl Res. 2021 Dec;14(6):1104-1113. doi: 10.1007/s12265-021-10117-9. Epub 2021 Mar 15.

Abstract

Thrombocytopenia after TAVI is common and clinically detrimental. Retrospectively, we observed Portico recipients had a more profound platelet drop than Evolut recipients. We thus investigated periprocedural platelet damage and/orpro-inflammatory state in 64 TAVI recipients at baseline and after implantation. Platelet damage was assessed by annexin V staining and monocyte-phagocytic phenotype was assessed according to CD14/CD36 expression. Serum cytokines were measured in 20 patients. The formaldehyde-based storage solution altered platelets. When, before being loaded onto the delivery system, Portico underwent one additional flushing to those recommended, the receiving patients showed thrombocytopenia, platelet damage, and CD36-monocyte count were mitigated. A general increase in IL-6 was recorded in overall TAVI recipients, but a high serum level of IL-8, a potent thrombocytopenia inducer, was measured in Portico recipients only, including those with extra-rinsed valve. Our study suggests a platelet-injury effect by storage-solution and generates the hypothesis of a role for the biomaterial in stimulating innate-immunity. Larger prospective studies are needed. Graphical Abstract.

Keywords: Inflammatory cytokines; Phagocytic monocytes; Platelet cell death; TAVI; Thrombocytopenia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Biomarkers / blood
  • Bioprosthesis*
  • Cytokines / blood
  • Female
  • Heart Valve Prosthesis*
  • Humans
  • Italy
  • Male
  • Postoperative Complications / etiology*
  • Prosthesis Design
  • Retrospective Studies
  • Thrombocytopenia / etiology*
  • Transcatheter Aortic Valve Replacement / instrumentation*

Substances

  • Biomarkers
  • Cytokines